Discover a groundbreaking webinar delving into the benefits of digital and quantitative multiplexed assays for protein and RNA tumor microenvironment profiling. Pancreatic and colorectal cancer are two of the four tumor types with the highest aggregate mortality rates in the United States. Despite extensive research, genomically-directed therapies benefit only a minority of these patients. The Wolpin-Nowak laboratory at the Dana-Farber Cancer Institute works to understand the cellular composition and functional status of these deadly tumors in order to detect cancer earlier and develop new therapies for patients.
To accomplish these goals, the experts from Leica Biosystem use digital imaging, supervised machine learning, customized analysis pipelines and in-house developed multiplex assays designed specifically for interrogating these tumor types. They design these assays to be run in an automated, reproducible manner that enables uniform analysis of many specimens. Cumulatively, they have analyzed tissue from more than 4,000 patients across large landscape cohorts of tumors and as part of clinical trial correlative studies.
In this webinar, the featured speaker will review representative multiplexed assays for protein and RNA profiling that have been built in the lab and will discuss the necessary elements to operationalize this type of testing in a translational research laboratory. He will also explore the advantages of different types of assays and key considerations for ensuring consistently high data quality at the scale spanning hundreds to thousands of specimens.
Join this webinar to gain insights into spatial protein and RNA profiling for pancreatic and colorectal tumor microenvironment analysis.
Jonathan Nowak, MD, PhD, Molecular and GI Pathologist, Brigham and Women's Hospital & Assistant Professor of Pathology, Harvard Medical School
Dr. Jonathan Nowak is a Molecular and Gastrointestinal Pathologist at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, and an Assistant Professor of Pathology at Harvard Medical School in Boston. He is board-certified in anatomic and clinical pathology and molecular genetic pathology. As the associate director for the Brigham and Women’s Center for Advanced Molecular Diagnostics, Dr. Nowak oversees next-generation sequencing assays for solid tumors and hereditary cancer predisposition. Dr. Nowak also runs a research laboratory at the Dana-Farber focused on multi-omic tissue-based analysis of pancreatic and colorectal cancers.
Who Should Attend?
This webinar will appeal to scientists and cancer researchers interested in advancing translational science employing chromogenic and fluorescent protein and RNA spatial profiling technologies to study human tissue specimens in the following industries:
What You Will Learn
Attendees will gain insights into:
- The benefits of digital, quantitative tumor microenvironment profiling over traditional qualitative approaches
- The different types of protein and RNA spatial profiling approaches that are compatible with formalin-fixed paraffin-embedded tissue
- The laboratory and computational requirements for designing and analyzing multiplex immunofluorescence assays
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Leica Biosystems is headquartered in Germany and operates in over 100 countries.